Amedisys Inc

Amedisys — Q3 2016 Earnings Presentation

20 slides from Amedisys's earnings presentation, Nov 3, 2016

  1. Slide 1: Amedisys 3Q16 Earnings Call Supplemental Materials

    Amedisys 3Q16 Earnings Call Supplemental Materials November 2016 Exhibit 99.2

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and u

  3. Slide 3: Highlights and Summary Financial Results (Adjusted) – 3Q 2016

    Highlights and Summary Financial Results (Adjusted) – 3Q 2016 (1) Amedisys Consolidated Revenue Growth: +11% EBITDA: $26M EBITDA Margin: 7.1% EPS: $0.36 Amedisys Highlights Same Store Admissions: Medicare FFS: +1% Total Episodic: +3% Non-episodic: (7%) Other Statistics: Medicare recert rate (3): 35%

  4. Slide 4: Home Health and Hospice Segment (Adjusted) – 3Q 2016

    Home Health and Hospice Segment (Adjusted) – 3Q 2016 (1) Medicare same store growth positive but below plan (+1%); revenue mix holding steady (76% Medicare FFS) Non-Medicare per visit admissions declined 7% during 3Q16 compared to prior year CPV increase driven by planned salary increases, HCHB disr

  5. Slide 5: General & Administrative Expenses – Adjusted

    General & Administrative Expenses – Adjusted (1,2) Highlights Year over year total G&A as a percentage of revenue decreased of 80 basis points despite inclusion of roughly $7M related to acquisitions; declined 130 bps since high point in 1Q16 Home health segment G&A: 40 bps y/y increase as % of reve

  6. Slide 6: Amedisys Strategy: Four Areas of Focus

    Amedisys Strategy: Four Areas of Focus Updated 3Q 2016 Clinicians Patient Health Clinicians Patient Health Outstanding Outcomes for Our Patients In Their Homes Amedisys Care Centers & Clinical Teams Current: All centers went live on HCHB Oct. 31, 2016 Over 90% of savings initiatives currently underw

  7. Slide 7: How We're Tracking

    How We’re Tracking Clinical Distinction Employer of Choice Operational Excellence & Efficiency Driving Growth Outstanding Outcomes for Our Patients In Their Homes Care Centers & Clinical Teams Status Category Update Ongoing Initiative STARS Good progress on QPC Stars with January 17 preview score of

  8. Slide 8: Clinical Distinction: Improvements in Stars Metric

    Clinical Distinction: Improvements in Stars Metric Jul 16 Release Oct 16 Release Jan 17 Preview Quality of Patient Care 3.59 3.74 3.91 Entities at 4+ Stars 36% 50% 65% Quality of Patient Care (QPC) Value Based Purchasing QPC Star Average PS Star Average Amedisys VBP State Avg 3.83 3.64 Large Cohort

  9. Slide 9: Quality Correlations – Growth and Turnover

    Quality Correlations – Growth and Turnover Investment in quality to drive clinical distinction shows correlation with growth and turnover General trend is accelerating growth for 4+ STAR rated agencies (6% overall) Similar trend for turnover Correlation between STAR ratings and growth is statistical

  10. Slide 10: Becoming Employer of Choice: Improving Return on Human Capital

    Becoming Employer of Choice: Improving Return on Human Capital Total voluntary turnover continues to decline, closing in on goal of 22% by end of 2016 Corporate and two regions have achieved annual goal Implementation of HCHB allowing for increase in productivity targets Piloting proprietary resourc

  11. Slide 11: Operational Excellence: Roadmap to EBITDA Improvement

    Operational Excellence: Roadmap to EBITDA Improvement HCHB disruption cost deeper than originally estimated but still contained to 2016 Disruption ($M) Incremental disruption driven by: recert rate impact, increased: OT pay, wireless, mileage, and other back office costs Revised Disruption: ~$18,000

  12. Slide 12: Operational Excellence: Roadmap to EBITDA Improvement

    $46M in annualized savings identified - increased visibility into efficiency initiatives *Run rate: $46.4M Efficiencies and Disruption ($M) Operational Excellence: Roadmap to EBITDA Improvement All centers officially on HCHB Nov. 1. Disruption costs have been deeper than originally estimated but con

  13. Slide 13: Operational Excellence: HCHB Implementation Timeline

    Operational Excellence: HCHB Implementation Timeline During 3Q 2016 ~50% of our patient census were in some phase of HCHB implementation. Note: Since rollout started, 1 Hospice and 2 Home Health centers closed Clinician adoption to new workflow Reporting and clinical excellence classes have been eff

  14. Slide 14: Cost Per Visit Components

    $82.86 $79.01 Components 3Q’15 3Q’16 Variance Detail Mitigation Plan Salaries $60.12 $62.34 $2.22 $1.00 driven by salary increases $0.50 HCHB disruption due to Admin/OT $0.40 clinician mix Expect normal levels post HCHB. Will reduce as rollout is completed Initiative focused on optimizing clinician

  15. Slide 15: Driving Top Line Growth: Positive Metrics Across Business Segments

    Driving Top Line Growth: Positive Metrics Across Business Segments We continue to grow across all lines of business 234 Opportunities Prospected 45 Opportunities Under Review 13 Active Processes * Includes 3,792 (Q1), 3,958 (Q2) and 3,608 (Q3) completed episodes from Infinity acquisition 7% Growth 1

  16. Slide 16: CMS Update: Home Health and Hospice Reimbursement

    CMS Update: Home Health and Hospice Reimbursement Pending detailed claims analysis of Final Rule Home Health Medicare Reimbursement FY16 FY17 Proposed Market basket update 2.3% 2.8% Productivity adjustment (0.4%) (0.5%) Rebasing (2.4%) (2.3%) Nominal case-mix adjustment (1.0%) (1.0%) Net impact – In

  17. Slide 17: Debt and Liquidity Metrics

    Debt and Liquidity Metrics Net debt defined as total debt outstanding ($97M) less cash balance ($9M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($107M). Liquidity defined as the sum of cash balance and available revolving line of credit. Despite deploy

  18. Slide 18: Adjusted EBITDA to Free Cash Flow Reconciliation

    Adjusted EBITDA to Free Cash Flow Reconciliation (1,2) The financial results for the three-month periods ended September 30, 2015, December 31, 2015, March 31, 2016, June 30, 2016, and September 30, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconcil

  19. Slide 19: Income Statement Adjustments

    Income Statement Adjustments (1) The financial results for the three-month periods ended September 30, 2015, December 31, 2015, March 31, 2016, June 30, 2016, and September 30, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GA

  20. Slide 20: Amedisys

    AMEedISYS Damage from the Great Flood of 2016, East Baton Rouge Parish , Louisiana Photo by Paul Kusserow

Amedisys — Q3 2016 Earnings Presentation on 6ix